C Lübbert1, D Becker-Rux, A C Rodloff, S Laudi, T Busch, M Bartels, U X Kaisers. 1. Division of Infectious Diseases and Tropical Medicine, Department of Gastroenterology and Rheumatology, Leipzig University Hospital, 04103, Leipzig, Germany, christoph.luebbert@medizin.uni-leipzig.de.
Abstract
PURPOSE: From mid-2010 to early 2013 there was a large single-center (Leipzig University Hospital, Germany) outbreak of Klebsiella pneumoniae carbapenemase (KPC) type 2 producing K. pneumoniae (KPC-2-KP) involving a total of 103 patients. The aim of this study was to compare KPC-positive liver transplant recipients (LTR) and KPC-negative controls to determine both the relative risk of infection following colonization with KPC-2-KP and the case fatality rate associated with KPC-2-KP. METHODS: The study cohort of this retrospective observational study comprised nine patients who had undergone orthotopic liver transplantation (LTx) (median age of 52 years, range 28-73 years) with confirmed evidence of colonization with KPC-2-KP. The data from these nine LTR were matched to 18 LTR (1:2) in whom carbapenem-resistant pathogens were not present and compared for clinical outcomes. RESULTS: Of these nine cases, eight (89 %) progressed to infection due to KPC-2-KP, and five (56 %) were confirmed to have bloodstream infection with KPC-2-KP. Matched-pair analysis of KPC-positive LTR and KPC-negative controls revealed a substantially increased relative risk of 7.0 (95 % confidence interval 1.8-27.1) for fatal infection with KPC-2-producing K. pneumoniae after transplantation with a mortality rate of 78 % (vs. 11 %, p = 0.001). CONCLUSIONS: Colonization with KPC-2-KP in LTR leads to high infection rates and excess mortality. Therefore, frequent screening for carbapenem-resistant bacteria in patients on LTx waiting lists appears to be mandatory in an outbreak setting. Patients with evidence of persistent colonization with KPC-producing pathogens should be evaluated with extreme caution for LTx.
PURPOSE: From mid-2010 to early 2013 there was a large single-center (Leipzig University Hospital, Germany) outbreak of Klebsiella pneumoniae carbapenemase (KPC) type 2 producing K. pneumoniae (KPC-2-KP) involving a total of 103 patients. The aim of this study was to compare KPC-positive liver transplant recipients (LTR) and KPC-negative controls to determine both the relative risk of infection following colonization with KPC-2-KP and the case fatality rate associated with KPC-2-KP. METHODS: The study cohort of this retrospective observational study comprised nine patients who had undergone orthotopic liver transplantation (LTx) (median age of 52 years, range 28-73 years) with confirmed evidence of colonization with KPC-2-KP. The data from these nine LTR were matched to 18 LTR (1:2) in whom carbapenem-resistant pathogens were not present and compared for clinical outcomes. RESULTS: Of these nine cases, eight (89 %) progressed to infection due to KPC-2-KP, and five (56 %) were confirmed to have bloodstream infection with KPC-2-KP. Matched-pair analysis of KPC-positive LTR and KPC-negative controls revealed a substantially increased relative risk of 7.0 (95 % confidence interval 1.8-27.1) for fatal infection with KPC-2-producing K. pneumoniae after transplantation with a mortality rate of 78 % (vs. 11 %, p = 0.001). CONCLUSIONS: Colonization with KPC-2-KP in LTR leads to high infection rates and excess mortality. Therefore, frequent screening for carbapenem-resistant bacteria in patients on LTx waiting lists appears to be mandatory in an outbreak setting. Patients with evidence of persistent colonization with KPC-producing pathogens should be evaluated with extreme caution for LTx.
Authors: L Linares; C Cervera; I Hoyo; G Sanclemente; F Marco; F Cofán; M J Ricart; M Navasa; A Moreno Journal: Transplant Proc Date: 2010-10 Impact factor: 1.066
Authors: D Ben-David; R Kordevani; N Keller; I Tal; A Marzel; O Gal-Mor; Y Maor; G Rahav Journal: Clin Microbiol Infect Date: 2011-07-01 Impact factor: 8.067
Authors: E J Ariza-Heredia; R Patel; E A Blumberg; R C Walker; R Lewis; J Evans; A Sankar; M D Willliams; J Rogers; C Milano; R R Razonable Journal: Transpl Infect Dis Date: 2012-05-25 Impact factor: 2.228
Authors: C Wendt; S Schütt; A H Dalpke; M Konrad; M Mieth; B Trierweiler-Hauke; M A Weigand; S Zimmermann; K Biehler; D Jonas Journal: Eur J Clin Microbiol Infect Dis Date: 2010-03-07 Impact factor: 3.267
Authors: F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan Journal: J Clin Microbiol Date: 1995-09 Impact factor: 5.948
Authors: Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi Journal: Antimicrob Agents Chemother Date: 2012-01-17 Impact factor: 5.191
Authors: M D Bergamasco; M Barroso Barbosa; D de Oliveira Garcia; R Cipullo; J C M Moreira; C Baia; V Barbosa; C S Abboud Journal: Transpl Infect Dis Date: 2011-10-28 Impact factor: 2.228
Authors: G B Orsi; A Bencardino; A Vena; A Carattoli; C Venditti; M Falcone; A Giordano; M Venditti Journal: Infection Date: 2012-10-16 Impact factor: 3.553
Authors: Tommaso Giani; Viola Conte; Salvatore Mandalà; Marco Maria D'Andrea; Francesco Luzzaro; Pier Giulio Conaldi; Paolo Grossi; Gian Maria Rossolini Journal: J Clin Microbiol Date: 2014-04-23 Impact factor: 5.948
Authors: Maristela Pinheiro Freire; Isabel C V S Oshiro; Ligia C Pierrotti; Patricia R Bonazzi; Larissa M de Oliveira; Alice T W Song; Carlos H Camargo; Inneke M van der Heijden; Flavia Rossi; Silvia F Costa; Luiz A C DʼAlbuquerque; Edson Abdala Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Marcus R Pereira; Brendan F Scully; Stephanie M Pouch; Anne-Catrin Uhlemann; Stella Goudie; Jean E Emond; Elizabeth C Verna Journal: Liver Transpl Date: 2015-12 Impact factor: 5.799